|Day Low/High||157.50 / 160.72|
|52 Wk Low/High||65.44 / 187.99|
The firm is obviously fast becoming a real player in creating treatment for certain cancers. The firm still loses money.
This biotech is on the front lines of oncology treatments.
Time to check the charts and indicators.
The aging population is creating a massive tailwind for companies that provide cutting-edge health care.
Good morning folks! As Doug heads off on vacation (something I'll be doing on Saturday myself), I'm sitting in today for him, and I'll be doing so again right before his return. We're in the second real week of the June-quarter earnings season, and ...
Market is pretty much where it has been all day, nicely positive across the board. Biotech up nearly 2% on the day. Gilead Sciences, Inc. , and Celgene Corp. , are two large caps on the move for reasons we covered in previous posts. The Bristol-Myer...
The Menlo Park, Calif.-based firm on Thursday reported third-quarter results and said it has hired Cowen to help with evaluating potential transactions.
The largest shareholder of Immunomedics, VenBio, asks for an injunction against its partnership with Seattle Genetics.
Stocks were up midday Tuesday as the Dow moves toward the 20,000 milestone and consumer confidence increases.
Selling in SGEN has created a huge upside vacuum; take advantage with this vertical call spread strategy.
The trade is once again the out-of-the-money, bullishly biased vertical call spread.
Shares of Grand Canyon Education (LOPE) have fallen over 18% so far in 2015, but they have still outperformed the rest of the beleaguered for-profit education sector.
TheStreet's Jim Cramer says newer pharmaceutical companies, like Celgene (CELG), Isis Pharmaceuticals (ISIS) and Seattle Genetics (SGEN), should be bought on any weakness because they have the potential to perform extremely well and may be better buys than Pfizer, Merck, Bristol-Myers and Eli Lilly.
For these kinds of growth stocks, you have no choice but to wait.
Here are some specific stocks working as parables right now.